Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253473 · ClinicalTrials.gov registry record · Phase 4
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
A Phase 4 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT01253473 is a Phase 4 study that has completed, run by National Jewish Health. The registered enrollment target is 46 participants.
The verdict
NCT01253473, a Phase 4 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
The main objective of the study is to see if using anti-inflammatory to patients with airway disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than using these treatments in patients with loss of lung tissue. Symbicort plus ipratropium/albuterol will be used for 12 weeks in an open-label study in subjects with airway predominant COPD.
Interventions
- DRUG budesonide/formoterol
- DRUG Budesonide
- DRUG Ipratropium/albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2012-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253473
The ClinicalTrials.gov registry entry for NCT01253473 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which budesonide/formoterol is the first listed.
NCT01253473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253473 about?
NCT01253473 is a clinical study titled "Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)". The main objective of the study is to see if using anti-inflammatory to patients with airway disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than using these treatments in patients with loss of lung tissue. Symbicort plus ipratropium/albuterol will be used for 1...
What is the current status of trial NCT01253473?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2012-04. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01253473?
The interventions under investigation include: budesonide/formoterol (DRUG), Budesonide (DRUG), Ipratropium/albuterol (DRUG).
Who is sponsoring clinical trial NCT01253473?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.